The test works by identifying sugars, known as glycans, in blood. These sugars are attached to protein molecules called PSA and are known to undergo distinct but subtle changes when cancer is present in the body.
Particular types of glycans are associated with different cancers — but until now, there has been no technology available to detect the glycans in an accurate, timely and sufficiently specific way.
